1. Pink Sheet

Supplement Claim Ruling Rejects FTC View Of “Competent And Reliable” Evidence

 
• By Dan Schiff

In a decision that suggests FTC may have to broaden what it considers competent and reliable evidence, a federal court in Florida rules supplement firm Garden of Life performed adequate due diligence in making claims and was not in contempt of an order for permanent injunction.

A federal judge strikes a blow against the Federal Trade Commission’s nutritional product advertising enforcement, ruling that supplement firm Garden of Life LLC performed adequate due diligence in making health and label claims and thus was not in contempt of an order for permanent injunction.

The Feb. 27 decision from the U.S. District Court for the Southern District of Florida suggests FTC may have to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

UK’s Decentralized Manufacturing Rules Designed To Allow For ‘Future Developments’

 
• By Eliza Slawther

The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.

Global Guideline Signals ‘Paradigm Shift’ For Pregnant And Breastfeeding Women, Says EMA

 
• By Anabel Costa-Ferreira

The European Medicines Agency expects the International Council for Harmonization’s new guideline will help address the critical lack of data on the use of medicinal products in pregnant and breastfeeding populations.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges